Aemetis (NASDAQ:AMTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $28.00 target price on the specialty chemicals company’s stock. HC Wainwright’s price target would suggest a potential upside of 275.34% from the stock’s previous close. HC Wainwright also issued estimates for Aemetis’ FY2025 earnings at $0.89 EPS.
AMTX has been the subject of a number of other research reports. Truist Financial cut their target price on Aemetis from $5.00 to $2.50 and set a “hold” rating on the stock in a research note on Thursday, April 13th. Piper Sandler lifted their price objective on shares of Aemetis from $2.00 to $3.00 in a research note on Tuesday, June 6th. Finally, Stifel Nicolaus increased their target price on shares of Aemetis from $9.00 to $9.50 in a report on Friday, July 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Aemetis has a consensus rating of “Hold” and an average price target of $12.21.
Aemetis Price Performance
Shares of NASDAQ:AMTX opened at $7.46 on Friday. The company has a 50 day moving average of $6.79 and a 200-day moving average of $4.40. Aemetis has a one year low of $1.16 and a one year high of $11.50. The stock has a market cap of $273.71 million, a price-to-earnings ratio of -1.84 and a beta of 1.30.
Insider Activity at Aemetis
In other Aemetis news, Director John R. Block sold 19,205 shares of the stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $6.30, for a total transaction of $120,991.50. Following the completion of the transaction, the director now owns 27,169 shares in the company, valued at approximately $171,164.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 14.34% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company bought a new position in Aemetis during the fourth quarter worth $49,000. Chapin Davis Inc. bought a new stake in shares of Aemetis during the 4th quarter worth about $63,000. Barclays PLC boosted its holdings in shares of Aemetis by 542.0% during the 4th quarter. Barclays PLC now owns 8,031 shares of the specialty chemicals company’s stock worth $32,000 after buying an additional 6,780 shares during the period. Hazlett Burt & Watson Inc. bought a new position in Aemetis in the 2nd quarter valued at about $73,000. Finally, Creative Planning lifted its position in Aemetis by 8.6% during the second quarter. Creative Planning now owns 101,717 shares of the specialty chemicals company’s stock worth $746,000 after acquiring an additional 8,094 shares during the last quarter. Institutional investors own 39.83% of the company’s stock.
About Aemetis
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products.
Featured Articles
- Five stocks we like better than Aemetis
- What Are Utility Stocks? An Overview of the Utilities Sector
- MarketBeat Week in Review – 07/31 – 08/04
- How and Why to Invest in Oil Stocks
- 3 Best Meme ETFs to Buy Now
- What is the NASDAQ Stock Exchange?
- XPO Keeps Reaching New Highs: Markets Love the Stock
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.
